Startseite Über uns Köpfe Prof. Dr. med. Margitta Worm
Allergologie
Prof. Dr. med. Margitta Worm
 

Allergologie

Prof. Dr. med. Margitta Worm

Allergie-Centrum-Charité
Klinik für Dermatologie, Venerologie und Allergologie
Charité Campus Mitte, Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Tel: +49 (0)30 450 518 105 Fax: +49 (0)30 450 518 958 margitta.worm@charite.de

CV - Akademischer Werdegang und Schlüsselpublikationen (nur auf Englisch verfügbar)

Short Biosketch

Prof. Dr. med. Margitta Worm has been appointed as an university professor for immune modulation of allergic diseases at the Charité – medical University Berlin.

She is the head of the Division of Allergy and Immunology of the Department of Dermatology and Allergy including the Clinical Experimental Allergy and Immunology unit of the Allergy-Center-Charité. She has a long-term expertise in clinical trials and her clinical and research interests include atopic dermatitis, eczema, anaphylaxis, food allergy, autoimmune skin diseases and immune modulation in allergy and immunology.

Margitta Worm has initiated and was involved in several national and international guidelines e.g. atopic eczema, anaphylaxis, cutaneous lupus and autoimmune blistering diseases. She is the initiator and speaker of the KFO 339 entitled food allergy and tolerance the president of the German allergy society (DGAKI) and an active member in several national and international societies (BDG, DDG, DGAKI, EAACI, WAO). Prof. Worm acts as an ad hoc reviewer for national and international dermatology and allergy journals.

Scientific Career
  • 2017 Director Division of Allergy and Immunology
  • 2012 – 2017 Director of outpatient clinic Dpt. Dermatology and Allergy
  • 2011 Coordinator for medical teaching and faculty member for medical education
  • 2007 Study coordinator in clinical trials; coordinating center for clinical studies Charité
  • 2003 Head of the clinical study unit allergy, Department of Dermatology and Allergy
  • 2003 Full professorship for immune modulation of allergic diseases Charité, Berlin
  • 2002 Board certification Allergy & Environmental Medicine
  • 2000 Assistant professor Dpt. Dermatology and Allergy Charité, Berlin
  • 1998 Board certification Dermatology and Venerology
  • 1995 – 2000 Clinical fellow in training Dpt. of Dermatology Charité, Berlin
  • 1993 – 1995 Postdoc research fellow at Children’s Hospital, Havard Medical School, Boston/USA
  • 1991 – 1993 Junior doctor and research fellow at Dpt. of Dermatology, FU-Berlin
  • 1991 Medical graduation at Freie Universität Berlin
Boards and Memberships

Boards

  • President of the Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)
  • Leader of food allergy group of Deutsche Gesellschaft für Allergologie und klinische Immunologie (DGAKI)
  • 2017 – 2019, chair in food allergy interest group of European Academy of Asthma, Allergy and Immunology (EAACI)
  • President of Network for Online-Registration of Anaphylaxis (NORA e.V)

Memberships and other Activities

  • member of Anaphylaxis Training and Education (AGATE e.V.)
  • Reviewer for German-Research Foundation (DFG)
  • Reviewer for JACI, Allergy, Clin Exp Allergy and others
  • elected member of german-research foundation (DFG) council clinical study and medical review board – section 4
Awards
  • 2011 Kanert award by Kanert foundation for research in Allergy
  • 2007 Award for pain research „Classical conditioning and expectancy in placebo hypoalgesia
Third Party Funding

Selection from 2017 – ongoing

  • 2017 – 2021 DFG TRR-130 TP 19 „Regulation der B-Zelldifferenzierung durch Vitamin A und D“
  • 2019 – 2022 DFG WO 541/16-2 „Cyclooxygenasen als Modulatoren allergischer Reaktionen, mechanistische Hintergründe und therapeutisches Potential“
  • 2020 – 2023 DFG WO 541/19-1 Food@ – KFO339
Key Publications
  1. Scholz J; Kuhrau J; Heinrich F; Heinz GA; Hutloff A; Worm M; Heine G (2021). Vitamin A controls the allergic response through T follicular helper cell as well as plasmablast differentiation. Apr;76(4):1109-1122.
  2. Treptow S; Grün J; Scholz J; Radbruch A; Heine G; Worm M (2021). 9-cis Retinoic acid and 1.25-dihydroxyvitamin D 3 drive differentiation into IgA + secreting plasmablasts in human naïve B cells. Eur J Immunol. Jan;51(1):125-137.
  3. Francuzik W; Ruëff F; Bauer A; Bilò MB; Cardona V; Christoff G; Dölle-Bierke S; Ensina L; Fernández Rivas M; Hawranek T; O’B Hourihane J; Jakob T; Papadopoulos NG; Pföhler C; Poziomkowska-Gęsicka I; Van der Brempt X; Scherer Hofmeier K; Treudler R; Wagner N; Wedi B; Worm M. (2021). Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry. J Allergy Clin Immunol. Feb;147(2):653-662.e9.
  4. Heine G; Francuzik W; Doelle-Bierke S; Drozdenko G; Frischbutter S; Schumacher N; Radbruch A; Worm M. (2021). Immunomodulation of high-dose vitamin D supplementation during allergen-specific immunotherapy. Allergy. Mar;76(3):930-933.
  5. Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M (2020). Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. Feb 1;156(2):131-143.
  6. Redhu D; Frank K; Kumari V; Francuzik W; Babina M; Worm M (2020). Thymic stromal lymphopoietin production induced by skin irritation results from concomitant activation of protease-activated receptor 2 and interleukin 1 pathways. Br J Dermatol. Jan;182(1):119-129.
  7. Worm M; Higenbottam T; Pfaar O; Mösges R; Aberer W; Gunawardena K; Wessiepe D; Lee D; Kramer MF; Skinner M; Lees B; Zielen S (2018). Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy. Allergy. Sep;73(9):1812-1822.
  8. Kettner A; DellaCorte G; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Simonsen K; Reymond C; Spertini F (2018). Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season. J Allergy Clin Immunol. Aug;142(2):678-680.e7.
  9. Muraro A; Fernandez-Rivas M; Beyer K; Cardona V; Clark A; Eller E; Hourihane JO; Jutel M; Sheikh A; Agache I; Allen KJ; Angier E; Ballmer-Weber B; Bilò MB; Bindslev-Jensen C; Camargo CA Jr; Cianferoni A; DunnGalvin A; Eigenmann PA; Halken S; Hoffmann-Sommergruber K; Lau S; Nilsson C; Poulsen LK; Rueff F; Spergel J; Sturm G; Timmermans F; Torres MJ; Turner P; van Ree R; Wickman M; Worm M; Mills ENC; Roberts G (2018). The urgent need for a harmonized severity scoring system for acute allergic reactions. Sep;73(9):1792-1800.
  10. Worm M; Higenbottam T; Pfaar O; Mösges R; Aberer W; Gunawardena K; Wessiepe D; Lee D; Kramer MF; Skinner M; Lees B; Zielen S (2018). Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy. Sep;73(9):1812-1822.
  11. Heine G; Hollstein T; Treptow S; Radbruch A; Worm M. (2018). 9-cis retinoic acid modulates the type I allergic immune response. J Allergy Clin Immunol. Feb;141(2):650-658.e5.
  12. Grabenhenrich LB; Dölle S; Ruëff F; Renaudin JM; Scherer K; Pföhler C; Treudler R; Koehli A; Mahler V; Spindler T; Lange L; Bilò MB; Papadopoulos NG; Hourihane JOB; Lang R; Fernández-Rivas M; Christoff G; Cichocka-Jarosz E; Worm M (2018). Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register. J Allergy Clin Immunol Pract. Mar 29.
  13. Heine G; Hollstein T; Treptow S; Radbruch A; Worm M (2017). 9-cis retinoic acid modulates the type I allergic immune response. J Allergy Clin Immunol. 2017 May 17. pii: S0091-6749(17)30762-5.
  14. Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M (2016). Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Jan 2;387(10013):40-52.
  15. Grabenhenrich LB; Dölle S; Moneret-Vautrin A; Köhli A; Lange L; Spindler T; Ruëff F; Nemat K; Maris I; Roumpedaki E; Scherer K; Ott H; Reese T; Mustakov T; Lang R; Fernandez-Rivas M; Kowalski ML; Bilò MB; Hourihane JO; Papadopoulos NG; Beyer K; Muraro A; Worm M (2016). Anaphylaxis in children and adolescents: The European Anaphylaxis Registry. J Allergy Clin Immunol. Apr;137(4):1128-1137.
  16. Nassiri M; Eckermann O; Babina M; Edenharter G, Worm M (2016). Serum levels of 9α,11β-PGF2 and cysteinyl leukotrienes are useful biomarkers of anaphylaxis. J Allergy Clin Immunol. Jan;137(1):312-4.
  17. Nassiri M; Babina M; Dölle S; Edenharter G; Ruëff F; Worm M (2015). Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol. 135(2):491-9.
  18. Heine G; Tabeling C; Hartmann B; Calera G; Carla R; Kühl A; Lindner J; Radbruch A; Witzenrath M; Worm M (2014). 25-Hydroxvitamin D3 Promotes the Long-Term Effect of Specific Immunotherapy in a Murine Allergy Model. J Immunol, 193(3):1017-23.
  19. Milovanovic M; Heine G; Hallatschek W; Opitz B; Radbruch A; Worm M (2010). Vitamin D receptor binds to the germline gene promoter and exhibits transrepressive activity. J Allergy Clin Immun. 126(5):1016-23, 1023.e1-4.
  20. Worm M; Krah J M; Manz R A; Henz B M (1998). Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood. 1;92(5):1713-20.
AG Worm
Irrwege des Immunsystems verstehen und korrigieren
Seite drucken
Seite teilen
DRFZ NewsFlash abonnieren